发表一篇学和医学成像类SCI论文
需要多少钱?
Benefits and limitations of middle bile duct segmental resection for extrahepatic cholangiocarcinoma.
切换为中文
Abstract:
BACKGROUND:Pancreaticoduodenectomy (PD) is a standardized strategy for patients with middle and distal bile duct cancers. The aim of this study was to compare clinicopathological features of bile duct segmental resection (BDR) with PD in patients with extrahepatic cholangiocarcinoma. METHODS:Consecutive cases with extrahepatic cholangiocarcinoma who underwent BDR (n = 21) or PD (n = 84) with achievement of R0 or R1 resection in Kobe University Hospital between January 2000 and December 2016 were enrolled in the present study. RESULTS:Patients who underwent PD were significantly younger than those receiving BDR. The frequency of preoperative jaundice, biliary drainage and cholangitis was not significantly different between the two groups. The duration of surgery was longer and there was more intraoperative bleeding in the PD than in the BDR group (553 vs. 421 min, and 770 vs. 402 mL; both P<0.01). More major complications (>Clavien-Dindo IIIa) were observed in the PD group (46% vs. 10%, P<0.01). Postoperative hospital stay was also longer in that group (30 vs. 19 days, P = 0.02). Pathological assessment revealed that tumors were less advanced in the BDR group but the rate of lymph node metastasis was similar in both groups (33% in BDR and 48% in PD, P = 0.24). The rate of R0 resection was significantly higher in the PD group (80% vs. 38%, P<0.01). Adjuvant chemotherapy was more frequently administered to patients in the BDR group (62% vs. 38%, P = 0.04). Although 5-year overall survival rates were similar in both groups (44% for BDR and 51% for PD, P = 0.72), in patients with T1 and T2, the BDR group tended to have poorer prognosis (44% vs. 68% at 5-year, P = 0.09). CONCLUSIONS:BDR was comparable in prognosis to PD in middle bile duct cancer. Less invasiveness and lower morbidity of BDR justified this technique for selected patients in a poor general condition.
展开更多
Hepatobiliary & Pancreatic Diseases International
HEPATOB PANCREAT DIS
| 最新影响因子：3.355 | 期刊ISSN：1499-3872 | CiteScore：1.65 |
| 出版周期：Bimonthly | 是否OA：YES | 出版年份：2002 |
期刊官方网址：http://www.hbpdint.com
| 自引率：5.70% | 研究方向：医学-胃肠肝病学 |
| 出版地区：PEOPLES R CHINA |
SCI期刊coverage：Science Citation Index Expanded（科学引文索引扩展）
专业编辑在线一对一答疑及时解决您的问题
Hepatobiliary & Pancreatic Diseases International 期刊简介
英文简介：
Published by Zhejiang University School of Medicine, China. ISSN: 1499-3872. Hepatobiliary & Pancreatic Diseases International (HBPD INT) publishes peer-reviewed original papers, reviews and editorials concerned with clinical practice and research in the fields of hepatobiliary and pancreatic diseases. Papers cover the medical, surgical, radiological, pathological, biochemical, physiological and historical aspects of the subject areas under the headings Liver, Biliary, Pancreas, Transplantation, Research, Special Reports, Editorials, Review Articles, Brief Communications, Clinical Summary, Clinical Images and Case Reports. The journal also deals with the basic sciences and experimental work. All submitted papers are reviewed by at least two referees expert in the field of the submitted paper. For detailed instructions concerning the submission of manuscripts, please refer to the Instructions for Authors in each issue of the journal. HBPD INT is published bimonthly since 2007.
中文简介：（来自Google、百度翻译）
浙江大学医学院出版，中国。ISSN: 1499 - 3872。 国际肝胆胰疾病组织(HBPD INT)发表同行评议的原创性论文、评论和社论，涉及肝胆胰疾病领域的临床实践和研究。论文涵盖了医学、外科、放射学、病理学、生物化学、生理和历史方面的主题领域，标题下包括肝脏、胆道、胰腺、移植、研究、专题报道、社论、综述文章、简要交流、临床总结、临床影像和病例报告。该杂志还涉及基础科学和实验工作。所有提交的论文都由至少两名论文领域的评审专家评审。关于投稿的详细说明，请参阅每期期刊的作者说明。《HBPD国际》自2007年起双月刊出版。
申请加急绿色通道，投稿周期比同行快2-3个月 现在咨询
Hepatobiliary & Pancreatic Diseases International 期刊中科院评价数据
最新中科院分区
| 大类(学科) | 小类(学科) | 学科排名 |
| 医学 |
GASTROENTEROLOGY & HEPATOLOGY (胃肠肝病学) 4区 |
72/80 |
最新公布的期刊年发文量
| 年度总发文量 | 年度论文发表量 | 年度综述发表量 |
| 73 | 61 | 12 |
总被引频次：1672
特征因子：0.002180
影响因子趋势图
无法辨别期刊质量？专业编辑老师一对一讲解，现在咨询现在咨询
Hepatobiliary & Pancreatic Diseases International 期刊CiteScore评价数据
最新CiteScore值
1.65
=
引文计数(2018)
文献(2015-2017)
=
459次引用
278篇文献
文献总数（2014-2016）：278
被引比率：60%
SJR：0.711
SCLmago期刊等级衡量经过加权后的期刊受引用次数，引用次数的加权值由施引期刊的学科领域和声望(SJR)决定。
SNIP：0.695
每篇文章中来源出版物的标准化影响将实际受引用情况对照期刊所属学科领域中预期的受引用情况进行衡量。
CiteScore排名
| 序号 | 类别 | 排名 | 百分位 |
| 1 |
大类(学科)：Medicine
小类(学科)：Hepatology
|
#38/59
点击查看排名表
|
|
| 2 |
大类(学科)：Medicine
小类(学科)：Gastroenterology
|
#65/128
点击查看排名表
|
|
CiteScore趋势图
Scopus涵盖范围
无法辨别期刊质量？专业编辑老师一对一讲解，现在咨询现在咨询
Hepatobiliary & Pancreatic Diseases International 期刊常见问题
热门常见问题
无法辨别期刊质量？专业编辑老师一对一讲解，现在咨询现在咨询
权益保障
-
刊物信息可查
推荐刊物均可到国家新闻出
版总署网站查询正刊 -
严格保密协协议
可签署保密协议 ，不透露任
何用户信息可跟踪进程，全程
协议 -
售后服务保障
1对1服务，7x24小时在线
-
企业信誉保障
16年经验沉淀，实体公司
运营
最新评论(不代表本站观点)
-
liting7111
研究方向：肝胆胰 临床分析
审稿时间： 2个月内
去年你0月我投稿，审稿快，不过能明显感觉出来处理稿件速度有点慢。大修一次、小修一次，这个月才通知接收，提供了不少证明材料。2020-05-23 -
liting7111
研究方向：肝胆胰
接受率： 非常困难（几乎不命中）
最近刚投一篇，投稿三天秒拒，没给拒稿理由。2019-10-09 -
liting7111
研究方向：医学 胃肠肝病学
审稿时间： 2个月内
刚接收，编辑很友好，国内的一本SCI期刊，浙一主编，目前1.5分，审稿意见一般不超一个半月，之后会给一个月时间修改。我投稿到接受花了四个月时间，速度很快，版面费月不算高。2019-07-21 -
liting7111
审稿挺严，IF逐年都有提升，杂志主编对文章审理很严，杂志质量很不错。2019-03-02
相关期刊
-
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT...
影响因子：5.576
ISSN：0885-3924
研究方向：医学-临床神经学
-
AMERICAN JOURNAL OF CHINESE MEDICINE...
影响因子：6.005
ISSN：0192-415X
研究方向：医学-全科医学与补充医学
-
LANCET...
影响因子：202.731
ISSN：0140-6736
研究方向：医学-医学：内科
-
Clinics...
影响因子：2.898
ISSN：1807-5932
研究方向：医学-医学：内科
-
MEDICINE...
影响因子：1.817
ISSN：0025-7974
研究方向：医学-医学：内科
-
BMJ Open...
影响因子：3.006
ISSN：2044-6055
研究方向：MEDICINE, GENERAL & INTERNAL-
-
INTERNIST...
影响因子：0.834
ISSN：0020-9554
研究方向：医学-医学：内科
-
Hippokratia...
影响因子：0.522
ISSN：1108-4189
研究方向：MEDICINE, GENERAL & INTERNAL-
-
BMC Medicine...
影响因子：11.15
ISSN：1741-7015
研究方向：医学-医学：内科
Hepatobiliary & Pancreatic Diseases International 投稿经验
(由下方点评分析获得，4人参与，6528人阅读）